MedTrace Logo

Study Assessing Double-masked Uveitis Treatment

NCT01358266 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 592

Last updated 2019-07-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.

Conditions

  • Uveitis; Posterior, Disorder

Interventions

DRUG

DE-109 44 ug

Low dose

DRUG

DE-109 440 ug

Medium dose

DRUG

DE-109 880 ug

High dose

Sponsors & Collaborators

  • Santen Inc.

    lead INDUSTRY

Principal Investigators

  • Abu Abraham, MD · Santen Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2016-09-30
Completion
2016-12-31

Countries

  • United States
  • Argentina
  • Austria
  • Brazil
  • Chile
  • Colombia
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Japan
  • Peru
  • Poland
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01358266 on ClinicalTrials.gov